{
  "ticker": "CRBU",
  "company_name": "Caribou Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05722418",
      "title": "CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory Multiple Myeloma",
      "start_date": "2023-02-06",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Caribou Biosciences, Inc."
    },
    {
      "nct_id": "NCT04637763",
      "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma",
      "start_date": "2021-05-26",
      "completion_date": "2025-09",
      "enrollment": 0,
      "sponsor": "Caribou Biosciences, Inc."
    },
    {
      "nct_id": "NCT05332054",
      "title": "Long-Term Follow-up Study",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia",
      "start_date": "2022-03-16",
      "completion_date": "2041-12",
      "enrollment": 0,
      "sponsor": "Caribou Biosciences, Inc."
    },
    {
      "nct_id": "NCT06752876",
      "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis",
      "start_date": "2027-12",
      "completion_date": "2029-04",
      "enrollment": 0,
      "sponsor": "Caribou Biosciences, Inc."
    },
    {
      "nct_id": "NCT06128044",
      "title": "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory",
      "start_date": "2024-02-08",
      "completion_date": "2025-05-30",
      "enrollment": 0,
      "sponsor": "Caribou Biosciences, Inc."
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE1": 4,
      "": 1
    },
    "by_status": {
      "RECRUITING": 2,
      "ENROLLING_BY_INVITATION": 1,
      "WITHDRAWN": 1,
      "TERMINATED": 1
    },
    "active_trials": 3,
    "completed_trials": 0,
    "conditions": [
      "Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory",
      "Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma",
      "Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia",
      "Relapsed/Refractory Multiple Myeloma",
      "Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:52.639535",
    "search_query": "Caribou Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Caribou+Biosciences,+Inc."
  }
}